At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 101 enrolled
Drug / intervention
BMS-986207 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors
In Brief
A Phase 2 clinical trial evaluating BMS-986207, Nivolumab, and 1 other intervention for Broad Solid Tumor. Completed, enrolled 101 participants across 20 sites in 8 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and effectiveness of experimental medication BMS-986207 by itself, in combination with Nivolumab, and in combination with both nivolumab and ipilimumab in participants with solid cancers that are advanced or have spread.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBroad Solid Tumor
CountriesArgentina, Australia, Canada, Chile, Japan, Romania, Singapore, United States
CollaboratorsOno Pharmaceutical Co., Ltd.
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartNov 2016
Primary CompletionJan 2024
TodayJul 2026
First PostedSep 23, 2016
Enrollment StartNov 30, 2016
Primary CompletionJan 25, 2024
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 9.8 years ago
Interventions
BMS-986207drug
Specified dose on specified days
Nivolumabbiological
Specified dose on specified days
Ipilimumabbiological
Specified dose on specified days